Under the agreement, Celularity will provide Arthrex exclusive rights to distribute its placental-derived regenerative orthopedic products.
“Partnering with Celularity positions us to explore new opportunities in the orthobiologics space while continuing our mission of helping surgeons better treat their patients,” Arthrex senior director of orthobiologics, David Shepard, said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
